Provided by Tiger Trade Technology Pte. Ltd.

CAR-T Concept

1,924.50
-10.1012-0.52%
Number of Gainers:1
Number of Losers:1
Number of Flat:- -
PE:- -
High:1,939.71
Open:1,932.15
Low:1,916.02
Close:1,934.60
Volume:12.23M
Turnover:1.89B
Market Cap:495.88B
Float Cap:480.67B

Loading ...

Gilead Sciences Files Initial Beneficial Ownership Statement for EVP and General Counsel Keeley M. Cain Wettan

Reuters
·
2 hours ago

Gilead : TD Cowen Raises Target Price to $160 From $145

THOMSON REUTERS
·
Yesterday

Xilio Therapeutics Prices $40 Million Pre-Funded Warrant Offering

Reuters
·
Yesterday

Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Yesterday

Gilead Sciences Shares up 5.8% After Q4 Results Beat

THOMSON REUTERS
·
Yesterday

Gilead Sciences Stock Surges Over 5% as 2025 Net Profit Skyrockets Nearly 17-Fold

Stock News
·
Feb 11

Gilead Shares Reverse Premarket Course; Last up About 1%

THOMSON REUTERS
·
Feb 11

Gilead price target raised to $177 from $140 at Scotiabank

TIPRANKS
·
Feb 11

Gilead price target raised to $152 from $145 at Truist

TIPRANKS
·
Feb 11

BUZZ-U.S. STOCKS ON THE MOVE-McDonald's, Cloudflare, Gold miners

Reuters
·
Feb 11

Gilead : Deutsche Bank Raises Target Price to $155 From $135

THOMSON REUTERS
·
Feb 11

Gilead : Truist Securities Raises Target Price to $152 From $145

THOMSON REUTERS
·
Feb 11

U.S. Stocks to Watch: Moderna, Robinhood, Cloudflare, Lyft, Mattel, Beta Technologies, Gilead, and More

Dow Jones
·
Feb 11

Gilead Shares Fall 2.5% Premarket After Co Forecasts Annual Sales, Profit Below Estimates

THOMSON REUTERS
·
Feb 11

Gilead : Scotiabank Raises Target Price to $177 From $140

THOMSON REUTERS
·
Feb 11

Novartis’ treatment of progressive supranuclear palsy granted orphan designation

TIPRANKS
·
Feb 11

Gilead: Outlook FY26 Expect Cell Therapy to Decline 10% YoY, Reflecting Continued Competitive Headwinds- Presentation

THOMSON REUTERS
·
Feb 11

Gilead: Outlook FY26 Excluding Policy Headwinds, FY26 Hiv Sales Expected to Grow +8% Versus FY25- Presentation

THOMSON REUTERS
·
Feb 11

Gilead Sciences Publishes Fourth Quarter and Full Year 2025 MD&A Report

Reuters
·
Feb 11

Gilead Sciences Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
Feb 11